These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30043421)

  • 41. FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer.
    Neuzillet Y; van Rhijn BW; Prigoda NL; Bapat B; Liu L; Bostrom PJ; Fleshner NE; Gallie BL; Zlotta AR; Jewett MA; van der Kwast TH
    Virchows Arch; 2014 Aug; 465(2):207-13. PubMed ID: 24880661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
    Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
    Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
    Tomlinson DC; Baldo O; Harnden P; Knowles MA
    J Pathol; 2007 Sep; 213(1):91-8. PubMed ID: 17668422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence.
    Monteiro CRA; Korkes F; Krutman-Zveibil D; Glina S
    Einstein (Sao Paulo); 2022; 20():eAO6450. PubMed ID: 35384983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium.
    Røtterud R; Fosså SD; Nesland JM
    Histol Histopathol; 2007 Apr; 22(4):349-63. PubMed ID: 17290345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined analysis of smoking, TP53, and FGFR3 mutations in Tunisian patients with invasive and superficial high-grade bladder tumors.
    Ouerhani S; Rouissi K; Kourda N; Marrakchi R; Bougatef K; Riadh Ben Slama M; Sfaxi M; Chebil M; Ben Jilani S; Benammar Elgaaied A
    Cancer Invest; 2009 Dec; 27(10):998-1007. PubMed ID: 19909015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
    Barrows D; Feng L; Carroll TS; Allis CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25732-25741. PubMed ID: 32989154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
    Bernard-Pierrot I; Brams A; Dunois-Lardé C; Caillault A; Diez de Medina SG; Cappellen D; Graff G; Thiery JP; Chopin D; Ricol D; Radvanyi F
    Carcinogenesis; 2006 Apr; 27(4):740-7. PubMed ID: 16338952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice.
    Degoricija M; Korac-Prlic J; Vilovic K; Ivanisevic T; Haupt B; Palada V; Petkovic M; Karaman I; Terzic J
    J Transl Med; 2019 Nov; 17(1):394. PubMed ID: 31779626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.
    Williamson SR; Wang M; Montironi R; Eble JN; Lopez-Beltran A; Zhang S; Fan R; Wang L; Osunkoya AO; Koch MO; Cheng L
    Mod Pathol; 2014 Nov; 27(11):1540-8. PubMed ID: 24743222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice.
    Johnson DT; Hooker E; Luong R; Yu EJ; He Y; Gonzalgo ML; Sun Z
    PLoS One; 2016; 11(2):e0148851. PubMed ID: 26862755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
    Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
    Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urothelial carcinoma of the bladder in patients aged 30 years or younger: clinicopathological analysis and expression of fibroblast growth factor receptor 3 (FGFR3) of 45 cases.
    Huang H; Sun M; Li X; Jin J
    Med Oncol; 2015 May; 32(5):137. PubMed ID: 25801230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
    Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
    Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development.
    Vang DP; Wurz GT; Griffey SM; Kao CJ; Gutierrez AM; Hanson GK; Wolf M; DeGregorio MW
    J Vis Exp; 2013 Oct; (80):e50868. PubMed ID: 24300078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
    Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
    Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.